SAN DIEGO--(BUSINESS WIRE)--Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it will present data from multiple Phase 1 studies of RDEA594, its lead product candidate for the treatment of hyperuricemia and gout at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) in Copenhagen, Denmark.
